SinoMab Bioscience Ltd. (HK:3681) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
SinoMab BioScience Ltd. has announced the successful first dosing of a patient in a Phase 1b clinical trial in China for their novel SM17 treatment for Atopic Dermatitis. The treatment, which targets the IL-25 receptor to modulate Type II allergic reactions, has previously shown a good safety profile in Phase I trials. The company is optimistic about SM17’s potential as a more effective treatment option for patients unresponsive to current therapies.
For further insights into HK:3681 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue